Cengent Therapeutics

Cengent Therapeutics was a biotechnology company focused on structure-based drug discovery and computational protein structure prediction. The company utilized its proprietary "Gene-to-Lead" platform to accelerate the identification of drug candidates by determining the three-dimensional structures of proteins directly from genomic data. Originally founded as GeneFormatics, the firm aimed to bridge the gap between genomics and therapeutic development through high-throughput structural analysis. In 2003, Cengent was acquired by Structural GenomiX (later known as SGX Pharmaceuticals), which integrated Cengent's computational tools into its own drug discovery engine. The company's legacy lies in its early contributions to the field of structural proteomics and computer-aided drug design.